Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Using Nasal Broadband Glasses in the Initial Management of Severe Bronchiolitis in Infants Admitted in ICU (HFNC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02791711
Recruitment Status : Completed
First Posted : June 7, 2016
Last Update Posted : August 1, 2019
Sponsor:
Information provided by (Responsible Party):
Fondation Lenval

Brief Summary:

The aim of this study is to evaluate the use of nasal broadband glasses HFNC (High Flow Nasal Cannula) in the initial management of severe bronchiolitis in infants admitted in ICU.

Nasal HFNC can deliver warmed humidified gas through a nasal interface, greatly improving the safety and efficacy of administering O2. This device generates a continuous positive pressure in the airways, to reduce the work of breathing. The sealing absence of the HFNC at the nasal interface improves patient comfort and avoiding nasal trauma.


Condition or disease Intervention/treatment Phase
Bronchiolitis Other: High Flow Nasal Cannula Not Applicable

Detailed Description:

Bronchiolitis in infants is a common and potentially serious disease. It corresponds to an acute pulmonary disease and dyspnea usually viral (70 to 80% of Respiratory syncytial virus (RSV) in infants less than 1 year). It particularly affects infants under 2 years.

The 2001 consensus conference and bronchiolitis 2006 on the management clarified the criteria for hospitalization and simplified therapeutic attitudes. These conferences have highlighted the importance of humidification, the nasopharyngeal desobstruction for less severe forms of oxygen therapy and for others. Recent literature has also shown that the use of noninvasive ventilation type Continuous Positive Airway Pressure (CPAP) nasal or broadband nasal glasses (HFNC: High Flow Nasal canula) in severe forms possible to reduce the work of breathing of children with severe bronchiolitis and their use in studies "before / after" was accompanied by a significant decrease in the use of invasive ventilation.

The HFNC and nasal CPAP can deliver warmed humidified gas through a nasal interface, greatly improving the safety and efficacy of administering O2. These devices generate a continuous positive pressure in the airways, for decreasing the work of breathing. The sealing absence of the HFNC at the nasal interface improves patient comfort and avoiding nasal trauma, sometimes encountered with nasal CPAP interfaces.

The HFNC is a simple, effective and safe, commonly used in severe bronchiolitis admitted in ICU (Intensive Care Unit). However instead of this technique is not yet well defined.

The investigators assume that the use of HFNC in severe bronchiolitis in first line allows sufficient respiratory improvement to avoid recourse to other technical assistance ventilatory more binding.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Using Nasal Broadband Glasses HFNC (High Flow Nasal Cannula) in the Initial Management of Severe Bronchiolitis in Infants Admitted in ICU: Bicentric Observational Study on the 2013-2014 Epidemic
Study Start Date : December 2013
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Wear

Arm Intervention/treatment
High Flow Nasal Cannula
Use of High Flow Nasal Cannula
Other: High Flow Nasal Cannula
Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC




Primary Outcome Measures :
  1. Rate of early success for the number of bronchiolitis who once admitted in the ICU and placed HFNC will not need another support ventilation mode after one hour of treatment (H1) [ Time Frame: after one hour of treatment ]
    the number of children who once set HFNC at baseline Hour 0 will not need another breathing assistance technique After 1 hour H1 of treatment


Secondary Outcome Measures :
  1. Overall success rate [ Time Frame: Comparison between baseline Hour 0 and after 1 hour of treatment ]
    Number of children who will not need another technique while respiratory assistance throughout the ICU stay

  2. Demographic predictive factors of failure of HFNC [ Time Frame: At baseline hour 0 ]
    Correlation of demographic data Hour 0 to failure of HFNC

  3. Clinical predictive factors of failure of HFNC [ Time Frame: At baseline hour 0 ]
    Correlation of clinical data Hour 0 to failure of HFNC

  4. The child's comfort HFNC [ Time Frame: comparison to Hour 0, Hour 1, Hour 12 ]

    Neonatal pain and discomfort scale " Échelle Douleur Inconfort Nouveau-Né" (EDIN)) Scores comparison to Hour 0, Hour 1, Hour 12

    This scale evaluates the prolonged pain and discomfort of the child, an hetero assesor measures by 5 items about face, body, sleep, comfort and relationship. Each item scores from 0 to 5. 0 means no pain or discomfort symptoms and 5 means the maximum symptoms.

    Global score will be from 0 to 15.


  5. Incidence of adverse events in HFNC [ Time Frame: From baseline hour 0 to the end of hospitalization ]
    Frequency and types of adverse events throughout the ICU hospitalization period

  6. Effectiveness of HFNC after 1 hour of application [ Time Frame: Comparison between baseline Hour 0 and after 1 hour of treatment ]
    comparaison of clinical data between baseline and 1 Hour of HFNC application.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 1 Year   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • In which the diagnosis of bronchiolitis is strongly suspected (1st or nth episode). Acute bronchiolitis is defined by the presence of respiratory distress (wheezing, crackles auscultatory, wrestling signs) or apnea can not be explained by another existing pathology in children with a clinical history of upper respiratory infection.
  • Satisfactory at least 1 of the following severity criteria:

EN> 50 quiet,

  • Trouble consciousness / hypotonia,
  • Significant Apnea (with desaturation and / or bradycardia)
  • Hypercapnic acidosis (pH <7.3 and carbon dioxide partial pressure (PCO2)> 55mmHg)
  • Oxygen saturation (SpO2) <92% on room air
  • Including the holders of parental authority / legal representative are informed of the study and expressed no opposition to the participation of their child.
  • Affiliated with a social security scheme by one of the holders of parental authority / legal guardian

Exclusion Criteria:

  • Children with neuromuscular disease known heart or lung (even without decompensation) at the time of admission.
  • Any vital distress, including respiratory or neurological justifying intubation or other emergency resuscitation gesture.
  • Opposition to a parent / guardian to the participation of their children in the study.
  • Desire to study withdrawal expressed by one of the holders of parental authority / legal guardian
  • Voluntary or involuntary break current care protocol or research by the healthcare team.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02791711


Locations
Layout table for location information
France
Hôpital Arnaud de Villeneuve - CHU de Montpellier
Montpellier, France, 34295
Fondation LENVAL - Hôpitaux Pédiatriques de Nice CHU-LENVAL
Nice, France, 06200
Sponsors and Collaborators
Fondation Lenval
Investigators
Layout table for investigator information
Principal Investigator: Mickael AFANETTI, MD Fondation LENVAL - Hôpitaux Pédiatriques de Nice CHU-LENVAL

Layout table for additonal information
Responsible Party: Fondation Lenval
ClinicalTrials.gov Identifier: NCT02791711    
Other Study ID Numbers: 14-HPNCL-09
First Posted: June 7, 2016    Key Record Dates
Last Update Posted: August 1, 2019
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Fondation Lenval:
Bronchiolitis
Continuous Positive Airway Pressure
HFNC
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchiolitis
Bronchitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections